Document is current

Article History

Received: 11 August 2024

Accepted: 12 November 2024

First Online: 15 November 2024

Declarations

:

: RPM travel grants from Accord, BMS, MSD, lecture fees from BMS, GSK, Novartis, Roche; AD travel grants and lecture fees from Roche, BMS, Janssen, Molteni, MSD, Accord; ŁS travel grants from BMS, Accord; AD travel grants and lecture fees from BMS, MSD, Astellas, Merck, Servier, Astra Zeneca, Pfizer; JD travel grants and lecture fees from Amgen, AstraZeneca, BMS, MSD, Novartis, Nutricia; AGW travel grants and lecture fees from Roche, Novaris, Lili, Astellas, Pfizer, Amgen, Swixx, Pierre Fabre, Egis, BMS, MSD; AR travel grants and lecture fees from Roche, BMS, Ipsen, Pfizer, Novartis, Gilead, MSD; DTM travel grants and lecture fees from MSD, Pierre Fabre, BMS, Novartis, Pfizer; JW no declared; PB travel grants, lecture fees, and advisory boards from AstraZeneca, MSD, GSK, Pharma; MP travel grants and lecture fees from AstraZeneca, Roche, Novartis, Elli Lilly, Janssen, Gilead and Amgen;

: The study protocol was approved by the Bioethics Committee of Jagiellonian University Medical College (decision number 118.0043.1.115.2024 dated April 19, 2024).

: Standard institutional informed consent was obtained from each patient before initiating the nivolumab + ipilimumab treatment.

: Not applicable.